EU approves Novavax vaccine “90% preventative”… Station ‘5th’

A coronavirus vaccine developed by US pharmaceutical company Novavax has been conditionally approved for sale in Europe. In a clinical trial on adults 18 years of age and older, it was estimated that the effectiveness of preventing the corona virus reached 90%.

Correspondent Kim Jung-woo.

<기자>

The European Commission has approved the conditional sale of a COVID-19 vaccine developed by US pharmaceutical company Novavax.

The recombinant protein-based Novavax vaccine becomes the fifth vaccine approved for use in 27 EU member states, following Pfizer, Moderna, AstraZeneca, and Johnson & Johnson.

Earlier, the European Medicines Agency announced that in clinical trials conducted on 45,000 people in the United States, Mexico and the United Kingdom, the efficacy of Novavax vaccine was estimated to reach 90% in preventing COVID-19.

He then recommended that the vaccine be approved for use in adults 18 years of age or older if it meets EU standards in terms of efficacy, safety and quality.

[스탠리 에르크/노바백스 대표 : 우리는 내년 1월에 유럽으로 노바백스 백신을 들여올 예정으로 1분기 동안 노바백스 백신 2억 도즈를 생산할 수 있습니다.]

However, the European Medicines Agency said that there is still limited data on the effectiveness of prevention against omicron mutations.

In the midst of this, American pharmaceutical company Moderna said that booster shot, that is, the third booster vaccination with its vaccine, is effective against omicron mutation.

According to Bloomberg News, Moderna announced that “Analysis of the serum of 20 booster shot recipients showed that the neutralizing antibody in response to the omicron mutation was increased by 37 times.”

Currently, Moderna is also developing a vaccine for Omicron, which is expected to enter clinical trials as early as next year.